What Comes Next in Psoriasis Treatment: A Look at the Current Pipeline
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
Welcome to the IPC Psoriasis Masterclass for North America, an exclusive educational opportunity for early-to-mid-career dermatologists and other healthcare professionals actively managing and treating psoriasis. Focusing on fostering a small group environment, this FREE program offers an intimate and personalized learning experience, ensuring each participant receives the utmost attention and support.
Over the past seven years, we have successfully hosted the IPC Psoriasis Masterclass worldwide, including the Eastern Mediterranean and Africa, Latin America, Eastern Europe, and Asia, engaging nearly 1,500 participants from an impressive 65 countries. We are bringing this unique program to North America for the fourth time.
This Masterclass is led by an esteemed faculty of international experts boasting extensive experience in psoriasis care. We aim to equip attendees with cutting-edge skills and knowledge to elevate their careers and become leaders in psoriasis.
IPC will cover the cost of your 1-night stay at the Loews Chicago O’Hare Hotel and provide a reception on Saturday and breakfast on Sunday before the program begins.
Schedule:
Saturday, April 11
13:00 – Registration
14:00 – Program Begins
18:00 – Reception
Sunday, April 12
06:30 – Breakfast
08:00 – Program Begins
12:00 – Program Ends
The Masterclass is limited to 60 participants, selected from those dedicated to advancing their expertise in managing and treating psoriasis. If you are a Dermatologist, Nurse Practitioner, Physician Assistant, Dermatology Resident, or 3rd/4th year medical student from North America with a solid background in dermatology, this program is designed for you.
Thank you for your interest in attending the upcoming masterclass. Registration is now closed. If you would like to be placed on the waiting list, please email masterclass@psoriasiscouncil.org.
The IPC Psoriasis Masterclass for North America is an intensive, eight-hour educational program designed for early-to-mid-career dermatologists and healthcare professionals interested in specializing in psoriasis care. With a focus on fostering a small group environment, the Masterclass provides a personalized learning experience, empowering participants to excel in their careers and become leaders in psoriasis.
The agenda has been carefully designed to ensure participants gain the skills and knowledge required to manage patients effectively. Participants will engage in dynamic discussions, interactive Q&A sessions, and invaluable networking opportunities with distinguished experts in the field.
Learning Outcomes
Topics Covered
Prerequisites
The IPC Psoriasis Masterclass is for early-mid career dermatologists and other health professionals who are making treatment decisions and managing patients with psoriasis. Third/fourth-year medical students with a strong foundation in dermatology may also apply.
REGISTRATION – 1:00 pm
WELCOME + INTRODUCTION
Amy Paller, MS, MD, Illinois
The Science of Psoriasis: Pathogenesis and Genetics
Matthew Vesely, MD, PhD, Connecticut
Obesity and Cardiometabolic Disease
Vimal Prajapati, MD, FRCPC, DABD, Canada
Q & A
BREAK
Biologics and Biosimilars for Psoriasis
Kenneth Gordon, MD, Wisconsin
Oral Therapies for Psoriasis
Vimal Prajapati, MD, FRCPC, DABD, Canada
Topical Therapies for Psoriasis
Ronald Vender, MD, FRCPC, Canada
CASES: Optimizing Oral and Topical Therapies
Mio Nakamura, MD, MS, FAAD, Michigan
Q & A
Reception and Networking
REGISTRATION – 7:30 am
WELCOME DAY 2
Linda Stein Gold, MD, Michigan
Management of Psoriasis in Pediatrics
Amy Paller, MS, MD, Illinois
CASE: Pediatrics
DELEGATE
Psoriasis Involving High-Impact Sites
Linda Stein Gold, MD, Michigan
Psoriatic Arthritis for Dermatologists
Kenneth Gordon, MD, Wisconsin
CASE: Psoriatic Arthritis
DELEGATE
BREAK
Overview of Differential Diagnoses
Ronald Vender, MD, FRCPC, Canada
CASES: Differential Diagnoses
Mio Nakamura, MD, MS, FAAD, Michigan
CASE: Psoriasis During Pregnancy
DELEGATE
CASE: GPP
Matthew Vesely, MD, PhD, Connecticut
CASE: Cancer
DELEGATE
Q & A and Open Discussion
Closing Comments and Wrap-up
Co-Chairs
Loews Chicago O’Hare Hotel
5300 N River Rd.
Rosemont, IL 60018
Check-in: 16:00 | Check-out: 12:00
IPC will pay for a 1-night stay at Loews Chicago O’Hare Hotel in Chicago for each participant.
Travel Scholarship:
To help support participation, IPC is offering $500 travel scholarship for attendees traveling by air to Chicago, and $125 for local attendees and individuals traveling by car.
Transportation
Participants are responsible for arranging and financing their air and ground transportation to the event. We recommend booking your flights well in advance to secure the best rates and ensure that your travel plans allow attendance for the entire program.
The nearest airport to the venue, Loews Chicago O’Hare Hotel, is the Chicago O’Hare International Airport.
Ground
Loews Chicago O’Hare offers a complimentary airport shuttle between the hotel and Chicago O’Hare International Airport every 15 minutes, 24 hours a day, seven days a week.
Depending on traffic conditions, the estimated travel time from Chicago O’Hare International Airport to Loews Chicago O’Hare Hotel is approximately ten minutes by car.
Meals
An evening reception with heavy hors d’oeuvres and drinks will be provided on Saturday, April 11, and breakfast and breaks on Sunday, April 12.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.